PLG and neoplasm: Strikingly, these antibodies (in small scFv format) selectively blocked plasmin cleavage while not significantly interfering with the FasL engagement of the Fas receptor, as evident with the effective tumor cell-killing function in vitro and against the grafted tumors in vivo.